Compare · DNTH vs NVO
DNTH vs NVO
Side-by-side comparison of Dianthus Therapeutics Inc. (DNTH) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNTH and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $217.28B, about 39.2x DNTH ($5.54B).
- Over the past year, DNTH is up 432.5% and NVO is down 27.0% - DNTH leads by 459.5 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for DNTH).
- NVO has more recent analyst coverage (25 ratings vs 14 for DNTH).
- Company
- Dianthus Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $101.23+2.57%
- $49.08-0.41%
- Market cap
- $5.54B
- $217.28B
- 1M return
- +32.33%
- +11.62%
- 1Y return
- +432.51%
- -27.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 3
- 5
- Recent ratings
- 14
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DNTH
- EVP, CFO & CBO Savitz Ryan exercised 31,249 shares at a strike of $21.77 and sold $3,157,151 worth of shares (31,249 units at $101.03) as part of a pre-agreed trading plan (SEC Form 4)
- Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
- Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
- SVP, General Counsel and Sec. Veness Adam M exercised 30,000 shares at a strike of $17.88 and sold $2,423,958 worth of shares (30,000 units at $80.80) as part of a pre-agreed trading plan (SEC Form 4)
- Dianthus Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- EVP, Head of R&D Randhawa Simrat exercised 26,530 shares at a strike of $18.85 and sold $2,404,077 worth of shares (26,530 units at $90.62) as part of a pre-agreed trading plan (SEC Form 4)
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dianthus Therapeutics to Participate in Two Investor Conferences
- SEC Form 4 filed by Director Lawton Alison Frances
- SEC Form 4 filed by Director Romano Steven J.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S